TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Actual number recruited
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: L-arginine reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urinary Sodium Excretion (UNa+V)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: PANSS sum score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: immediate memory performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attendance at primary care visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to Progression (TtP)
Endpoint domain: Mortality/survival
Primary endpoint: Diabetes Mellitus normalization or improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hypertension improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hyperlipidemia improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: NPRQs and carbohydrate utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fat utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with recommended servings from each food group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dietary nutrient density of calcium, riboflavin, vitamin B6, and potassium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in tympanic temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of complementary and alternative medicine (CAM)
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Duration of caudal analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QOL score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: sleep apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: stress hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Nasal secretions scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pathological outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: prevention of ipsilateral stroke or TIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: freedom from restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Development of second primary cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: anxiety about the illness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: BAI (Beck Anxiety Inventory) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of renewed vaginal bleeds
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: task-related BOLD signal strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: performance accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: increase in vegetable servings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: increase in dietary fiber intake from grains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin response to GnRH stimulus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Circulating levels of A and T
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduced LF/HF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increased RMSSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete response rate (no vomiting)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: triacylglycerol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: HDL cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: mean utility values for mRS categories
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Respiratory arousal threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Adenocarcinoma-to-pancreas contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum glucose response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum triglycerides response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total plasma ghrelin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Physical task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of breast cancer (BC)
Endpoint domain: Mortality/survival
Primary endpoint: HAM-A score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Seizure worry subscale improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tympanic perforation closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-haemorrhagic stroke incidence
Endpoint domain: Mortality/survival
Primary endpoint: QIDS-C16 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of periprocedural myocardial infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: CK-MB rise within 6 hours following PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cTNI levels within 6 and 12 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ground reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of breast-feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Reduction of incontinent episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of erlotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C/D ratios of erlotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated oral CL/F of erlotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: meal frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite feeding score_1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite feeding score_2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral suppression (HIV‐1 RNA <50 copies/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hip bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in spine bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Successful intubation rate by 60s
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of serum VEGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DC numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean blood pressure index ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean patency time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Ability to discriminate odors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MDS‐UPDRS Part II + III TS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: sucking organization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sucking pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maturity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal polyp relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical complaints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum IL-7 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum MCP-1 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of exhaled NO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: complete clearance of the keloid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Femoral neck bone mineral density (FN-BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers of bone turnover markers (BTMs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of responders at week 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median percentage of bacteria removed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aneurysm rupture rate
Endpoint domain: Mortality/survival
Primary endpoint: PACU pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in plasma triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduction in plasma very low density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduction in LDL III concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hs-CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: platelet survival
Endpoint domain: Mortality/survival
Primary endpoint: SERS scores
Endpoint domain: Adverse events/effects
Primary endpoint: Effect index (EI) of CGI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: auditory stimulus suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for detection of poor health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net amount of iron absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Retention rates at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal staining criterion at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain reduction 50% or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in nodule size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dose limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: effectiveness of C-Neb compared to HDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: charges per treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in social anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: time to adequate clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AQLQ scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Wrinkle Severity Rating Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rate of syncope
Endpoint domain: Mortality/survival
Primary endpoint: Delayed vomiting incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of delayed emesis (mean number of emetic episodes per day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprocedure pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HF/NS problem rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: night sweat frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mood and quality of life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning
Primary endpoint: Change in urinary desmosine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor performance of affected elbows
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Urinary recovery of acetaminophen and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: head injury-related death
Endpoint domain: Mortality/survival
Primary endpoint: Change in cup-to-disc ratio (CDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lapatinib AUC0-24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lapatinib Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric fluid volume immediately after anesthesia induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric fluid pH immediately after anesthesia induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thirst and hunger levels before surgery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: transplantation outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of clazosentan infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Clearance of clazosentan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of distribution of clazosentan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean symptom scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ratings of surgical conditions
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of complete absence of pain (score=0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort reaction frequency
Endpoint domain: Adverse events/effects
Primary endpoint: plasma EIC restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma sCD14 level rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shortened hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Levels of RANTES
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of TGF‐beta1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total calcitriol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Phosphorus levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduced total score on SDSC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Quality of Life (Functional Assessment for Cancer Therapy-Ovarian)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sequential Organ Failure Assessment (SOFA) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative healing rates of ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Scores for physician's global assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total active joints improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low-Density Lipoprotein Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage of parturients with successful blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpartum hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Abnormal uterine contractions
Endpoint domain: Adverse events/effects
Primary endpoint: Life Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: reduced peer drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower rates of past 30-day other drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: higher coping skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of moderate or large patent foramen ovale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nNO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nEos levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RQLQ scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postprandial plasma levels of insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Five-year local recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Global cosmetic outcome at 5 years
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mast cell activation in middle ears
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Elevated tryptase levels in effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pharmacokinetics of volasertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-individual variability in total clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention in HIV care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hb(mass)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Triglycerides variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total cholesterol variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: regional failure
Endpoint domain: Mortality/survival
Primary endpoint: distant failure
Endpoint domain: Mortality/survival
Primary endpoint: Short-term adherence to HIV prevention and treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five-year overall survival (OS) rates
Endpoint domain: Mortality/survival
Primary endpoint: Antibody response rates to VZV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of bacterial infection
Endpoint domain: Adverse events/effects
Primary endpoint: surgical failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Volume of subcutaneous free fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in radius of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Decrease in wound index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: number of acute otitis episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Radiogenic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Post treatment value of TSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Status of euthyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: social participation in domestic life
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Flicker responses of retinal arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Flicker responses of retinal veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Retinal blood velocity response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in other RA symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes